Breast Cancer

Women taking bisphosphonates have less chance of developing invasive breast cancer than women who don’t take the bone-strengthening drugs.

Consistent with previous research, data presented Friday has found that a woman diagnosed with breast cancer is more likely to undergo mastectomy of the healthy breast, called prophylactic mastectomy, if she has an MRI and biopsy of that breast during treatment of the cancerous breast

Women with metastatic breast cancer (MBC) represent a growing number of breast cancer survivors worldwide, living often for many years with the challenges of ongoing treatment, debilitating side effects, and isolation. They advocate for themselves as they are able, but according to Musa Mayer, a metastatic breast cancer advocate, women with metastatic breast cancer around the world need increased attention, resources, and information on clinical trials that may prolong their lives.

A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Patients taking denosumab not only had fewer bone complications, but they took longer to develop compared with Zometa, reported researchers of a phase 3 study presented Thursday at the San Antonio Breast Cancer Symposium.

An enzyme called CYP2D6 converts tamoxifen to its active form, and some research has suggested that if the enzyme is blocked, tamoxifen won’t be as effective, thus causing patients to recur sooner than women with normal enzyme activity.

A drug that treats liver and kidney cancers delayed locally recurrent or metastatic HER2-negative breast cancer in two phase 2 studies presented Friday at the San Antonio Breast Cancer Symposium

Studies have suggested that MRI, along with mammography, is the best means of detecting breast cancer earlier among high-risk women.

When Dale Eastman was diagnosed with stage 3 breast cancer in 1990 at age 49, it turned the travel agent and mother into a driven advocate.

Krysti Hughett shares her experience as a breast cancer survivor and advocate.

For ER-positive breast cancer, researchers look to find which drugs work best, how they should be sequenced, and how long they should be taken.

The FDA decides to wait on reviewing Prolia (denosumab) for reducing treatment-related bone loss in breast and prostate cancer patients, but a new study may shed light on the drug’s importance.

Sexuality and intimacy issues often overlooked in breast cancer survivors.

Chronic inflammation causes cancer. Find out how and what's being done about it.

Cooling hot flashes brought on by cancer treatments.

Women ignite change across the globe.

Tamoxifen and antidepressants may not mix.

Fears can be magnified when a cancer diagnosis involves many unknowns, as is the case for triple-negative breast cancer.

Women from around the globe gathered at the Reach to Recovery International meeting to learn from others how to advocate for breast cancer survivors in their home countries.

After surgery, breast cancer patients are encouraged to exercise.

To learn more about managing cancer treatment-related hot flashes in men and women, CURE talked with Debra Barton, PhD, associate professor of oncology at the Mayo Clinic in Rochester, Minnesota.

There's now something to take aim at in triple-negative breast cancer.

What does Medicare cover when it comes to screening for colorectal cancer?

Despite the gains noted in the overall number of Medicare patients undergoing colonoscopy, researchers continue to see differences in colorectal cancer screening rates among certain groups, particularly minorities.

Newer targets found on cancer cells are providing scientists the ammunition to better treat cancer.

An infection reminds a breast cancer survivor that implants do not come with a lifetime guarantee.